Mereo BioPharma Reports Breakthrough in OI Fracture Study
Company Announcements

Mereo BioPharma Reports Breakthrough in OI Fracture Study

Mereo Biopharma Group Plc (MREO) has provided an announcement.

Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc announced promising 14-month results from their Phase 2 Orbit study, revealing a significant reduction in fracture rates in patients with Osteogenesis Imperfecta (OI) treated with setrusumab. The study showed both a substantial decrease in median annualized fracture rate by 67% and impressive improvements in bone mineral density (BMD) with no serious adverse events related to the treatment. These encouraging findings, set to be further detailed at an upcoming scientific meeting, underscore the potential of setrusumab to improve the lives of patients with OI.

For detailed information about MREO stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyMereo BioPharma reports Q3 EPS (2c), consensus (2c)
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyMereo BioPharma reports Q2 EPS (2c) vs 0c last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App